- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 9/12 - Antihypertensives
Patent holdings for IPC class A61P 9/12
Total number of patents in this class: 4000
10-year publication summary
163
|
134
|
193
|
277
|
260
|
259
|
292
|
297
|
236
|
96
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Daiichi Sankyo Company, Limited | 1849 |
74 |
Novartis AG | 10963 |
69 |
Takeda Pharmaceutical Company Limited | 2703 |
57 |
Actelion Pharmaceuticals Ltd | 534 |
41 |
Sunshine Lake Pharma Co., Ltd. | 585 |
38 |
Mitsubishi Tanabe Pharma Corporation | 581 |
36 |
United Therapeutics Corporation | 305 |
33 |
Taisho Pharmaceutical Co., Ltd. | 856 |
31 |
Acceleron Pharma Inc. | 357 |
27 |
F. Hoffmann-La Roche AG | 7912 |
25 |
Shionogi & Co., Ltd. | 869 |
24 |
Dainippon Sumitomo Pharma Co., Ltd. | 198 |
21 |
Boehringer Ingelheim Vetmedica GmbH | 1263 |
20 |
Institute of Materia Medica, Chinese Academy of Medical Sciences | 177 |
20 |
Nippon Shinyaku Co., Ltd. | 328 |
20 |
Bayer Pharma AG | 1061 |
19 |
Regeneron Pharmaceuticals, Inc. | 4211 |
19 |
University of Pittsburgh - Of the Commonwealth System of Higher Education | 3115 |
19 |
Janssen Pharmaceutica N.V. | 3431 |
18 |
Kowa Company, Ltd. | 1196 |
18 |
Other owners | 3371 |